Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Power Wins DPHARM Idol Disrupt 2024 by Connecting Patients and Sites to Clinical Trials with a Simplified Platform


News provided by

DPHARM

Sep 18, 2024, 12:10 ET

Share this article

Share toX

Share this article

Share toX


The Conference Forum is pleased to announce that Power is the winner of DPHARM Idol Disrupt at the 14th annual DPHARM: Disruptive Innovations to Advance Clinical Research 2024 event.

PHILADELPHIA, Sept. 18, 2024 /PRNewswire-PRWeb/ -- The Conference Forum is pleased to announce that Power is the winner of DPHARM Idol Disrupt at the 14th annual DPHARM: Disruptive Innovations to Advance Clinical Research 2024 event.

Power, represented by Brandon Li, Co-Founder, is building patient-friendly access to clinical trials, and is simplifying recruitment with a novel AI approach that delivers qualified referrals that match protocol criteria and supports the entire process through to enrollment.

"AI-driven curation of patient-friendly lay language is a game-changer. Power has unlocked access to clinical trials in a low-overhead, AI-forward way, and is helping patients not only find trials, but learn more about them and connect directly to a clinical research site," Nicole Sheetz, Gilead.

Post this

"Roughly 86% of all clinical trials are delayed due to an inability to recruit enough patients. By making it dead simple to discover and evaluate novel therapies, we're hoping to offer patients a source of hope while reducing the time it takes for new breakthrough drugs to reach approval," said Mr Li.

In front of 12 judges representing R&D executives, patient advocates, and life science investors, Power had six minutes to present how their platform helped patients navigate clinical trial options, scanned patient-uploaded medical documents for inclusion/exclusion criteria to match patients to potential trials, and let patients browse nearby sites. Mr Li also told the DPHARM audience that physicians and care providers had begun using the platform as well.

"AI-driven curation of patient-friendly lay language is a game-changer. Power has unlocked access to clinical trials in a low-overhead, AI-forward way, and is helping patients not only find trials, but learn more about them and connect directly to a clinical research site," said Nicole Sheetz, PharmD, Senior Director, Design & Innovation, Global Development, Gilead.

"Patients are always looking for information, and it's hard to make a decision in a pressurized environment. Power makes it clean, simple and user-friendly. When patients understand and retain information, especially from underrepresented communities, they are more likely to engage and exercise their options," said Karen Peterson, Founder and Chief Patient Advocate, Karen's Club.

Power had strong competition from the other DPHARM Idol Disrupt finalist contenders, which included:

  • Beaconcure, represented by Ilan Carmeli, COO and Co-Founder, and Sean Wall, SVP, Commercial
  • ThoughtSphere, represented by Avi Kulkarni, PhD, CEO
  • Inspire, represented by Brett Kleger, CEO
  • ProofPilot, represented by Chris Venezia, CEO
  • InSilicoTrials, represented by Mario Torchia, Chief Operating Officer, and MaryAnne Rizk, Advisor

The DPHARM Idol Disrupt 2024 judges were:

  • Mohammed Ali, R&D Head of Business Performance & Analytics, CMO Office, Astellas
  • Mary Brantner, Senior Director, Clinical Program Optimization and Innovation, Insmed Incorporated
  • Esther Dyson, Founder, Wellville
  • Bill Illis, Head, Technology and Collaboration, Novartis
  • Hassan Kadhim, Business Engagement Lead for Clinical Operations and Development, Vertex Pharmaceuticals
  • Karen Peterson, Founder and Chief Patient Advocate, Karen's Club
  • Doug Schantz, SVP, Clinical Operations, Asklepios BioPharmaceutical, Inc.
  • Nicole Sheetz, PharmD, Senior Director, Design & Innovation, Global Development, Gilead
  • Lauren Sunshine, Director, Product Management, Digital Health, BMS
  • Mark Travers, PhD, MBA, VP, Head Global Clinical Trial Operations, Regions and Regional Operations, Merck & Co., Inc.
  • Donna Usiskin, Chief Strategy Officer, New Enterprise Ventures
  • Henry Wei, MD, Head of Development Innovation, Regeneron Pharmaceuticals Inc

The DPHARM Idol Disrupt 2024 moderator was:

  • Sheryl Jacobs, VP, Global Development Operations, Amgen

For more information, please contact [email protected] or visit theconferenceforum.org.

About DPHARM:
DPHARM® offers an unparalleled opportunity to hear senior clinical operation executives and innovative thought leaders report on the latest innovations to Advance clinical trials. The concept of DPHARM was founded by Pfizer and Janssen, who continue to play a key role on the steering committee to deliver a highly relevant and engaging program.

About The Conference Forum:
The Conference Forum is a life science industry research firm that brings key people together to share and exchange ideas and information on how to get therapeutics to patients faster. We continue to examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common, patient-centered goals. Each of our key research areas – Clinical Trial Innovation, Patients as Partners, R&D Leadership, Immuno-Oncology, Drug Delivery and Clinical Research as a Care Option – has a dedicated conference, quarterly newsletter and podcasts.

Media Contact

Danny McCarthy, DPHARM, 646-350-2580, [email protected], https://dpharmconference.com/

SOURCE DPHARM

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.